-
★
Bivalent COVID Booster Ph 2/3 Interim Analysis (mRNA-1273.214)
(Hinzugefügt: 13.06.2022 um 09:32 Uhr)
https://s29.q4cdn.com/435878511/files/doc_presentations/2022/06/08/Master-Final-Bivalent-Omicron-Data-Update-0608.pdf
-
★
MODERNA ANNOUNCES ITS COVID-19 VACCINE PHASE 2/3 STUDY IN CHILDREN 6 MONTHS TO UNDER 6 YEARS HAS SUCCESSFULLY MET ITS PRIMARY ENDPOINT
(Hinzugefügt: 27.03.2022 um 08:13 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx
-
★
Booster mit mRNA-1273 führt nach 4 Wochen zu deutlichem Anstieg von neutralisierenden Antikörpern gegen Omikron
(Hinzugefügt: 20.12.2021 um 16:36 Uhr)
https://www.aerzteblatt.de/nachrichten/130253/Booster-mit-mRNA-1273-fuehrt-nach-4-Wochen-zu-deutlichem-Anstieg-von-neutralisierenden-Antikoerpern-gegen-Omikron
-
★
MODERNA ANNOUNCES PRELIMINARY BOOSTER DATA AND UPDATES STRATEGY TO ADDRESS OMICRON VARIANT
(Hinzugefügt: 20.12.2021 um 11:51 Uhr)
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Preliminary-Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant/default.aspx
-
★
Spikevax (previously COVID-19 Vaccine Moderna)
(Hinzugefügt: 18.10.2021 um 09:59 Uhr)
https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax
-
★
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
(Hinzugefügt: 23.09.2021 um 10:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2113017
-
★
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
(Hinzugefügt: 19.09.2021 um 14:41 Uhr)
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm
-
★
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
(Hinzugefügt: 18.02.2021 um 08:01 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102179
-
★
Product Information as approved by the CHMP on 6 January 2021, pending endorsement by the European Commission
(Hinzugefügt: 10.01.2021 um 09:32 Uhr)
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information_en.pdf
-
★
EMA: COVID-19 Vaccine Moderna
(Hinzugefügt: 10.01.2021 um 09:31 Uhr)
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-moderna
-
★
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
(Hinzugefügt: 31.12.2020 um 11:15 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
-
MODERNA ANNOUNCES OMICRON-CONTAINING BIVALENT BOOSTER CANDIDATE MRNA-1273.214 DEMONSTRATES SUPERIOR ANTIBODY RESPONSE AGAINST OMICRON
(Hinzugefügt: 24.06.2022 um 09:35 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx
-
Covid-19-Impfstoff von Moderna in der Schweiz für Kinder zwischen 6 und 11 Jahren zugelassen
(Hinzugefügt: 15.05.2022 um 10:28 Uhr)
https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-impfstoff-moderna-fuer-kinder-6-11-jahren-zugelassen.html
-
MODERNA FILES FOR AUTHORIZATION OF ITS COVID-19 VACCINE IN YOUNG CHILDREN SIX MONTHS TO UNDER SIX YEARS OF AGE
(Hinzugefügt: 30.04.2022 um 11:47 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Files-for-Authorization-of-Its-COVID-19-Vaccine-in-Young-Children-Six-Months-to-Under-Six-Years-of-Age/default.aspx
-
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
(Hinzugefügt: 27.04.2022 um 15:56 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00203-0/fulltext
-
Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine
(Hinzugefügt: 26.04.2022 um 13:35 Uhr)
https://www.researchsquare.com/article/rs-1555201/v1
-
MODERNA ANNOUNCES CLINICAL UPDATE ON BIVALENT COVID-19 BOOSTER PLATFORM
(Hinzugefügt: 26.04.2022 um 13:27 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Clinical-Update-on-Bivalent-COVID-19-Booster-Platform/default.aspx
-
COVID-19: Bivalenter Impfstoff von Moderna erzielt stärkere Boosterwirkung
(Hinzugefügt: 26.04.2022 um 13:23 Uhr)
https://www.aerzteblatt.de/nachrichten/133495/COVID-19-Bivalenter-Impfstoff-von-Moderna-erzielt-staerkere-Boosterwirkung
-
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron
(Hinzugefügt: 27.03.2022 um 07:52 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(22)00388-9
-
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
(Hinzugefügt: 11.03.2022 um 11:22 Uhr)
https://www.nature.com/articles/s41591-022-01739-w.epdf?sharing_token=eGurssEUn_J4gcNMTEP13NRgN0jAjWel9jnR3ZoTv0N1YipEX1TbaAre7g75CzBxMWX5rW_M1jAgmvopjV_QX-AlLVxwpz05ZRrVY4JowB87rmOy__6efAr94Vlg7JLAzx_tobVfSQPYRiTYMhR24t2x_WXT72-1Aij2gZle17Y%3D
-
EMA recommends approval of Spikevax for children aged 6 to 11 Share
(Hinzugefügt: 06.03.2022 um 18:59 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-approval-spikevax-children-aged-6-11
-
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
(Hinzugefügt: 17.02.2022 um 06:50 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119912
-
Moderna starts clinical trial of booster shot targeting omicron Covid variant
(Hinzugefügt: 17.02.2022 um 05:56 Uhr)
https://www.cnbc.com/2022/01/26/moderna-starts-clinical-trial-of-booster-shot-targeting-omicron-covid-variant.html
-
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice
(Hinzugefügt: 14.02.2022 um 16:10 Uhr)
https://www.biorxiv.org/content/10.1101/2022.02.07.479419v1
-
mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern
(Hinzugefügt: 10.01.2022 um 11:27 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(22)00030-9
-
STIKO prüft Moderna für unter 30-Jährige
(Hinzugefügt: 23.12.2021 um 19:48 Uhr)
https://www.aerzteblatt.de/nachrichten/130350/STIKO-prueft-Moderna-fuer-unter-30-Jaehrige
-
COVID-19: Myokarditis in Dänemark nach Moderna-Impfstoff häufiger
(Hinzugefügt: 18.12.2021 um 14:34 Uhr)
https://www.aerzteblatt.de/nachrichten/130201/COVID-19-Myokarditis-in-Daenemark-nach-Moderna-Impfstoff-haeufiger
-
Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies
(Hinzugefügt: 17.12.2021 um 13:14 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.15.21267805v1
-
Booster kann schwächere neutralisierende Wirkung von mRNA-1273 gegen Omikron teilweise ausgleichen
(Hinzugefügt: 17.12.2021 um 09:50 Uhr)
https://www.aerzteblatt.de/nachrichten/130160/Booster-kann-schwaechere-neutralisierende-Wirkung-von-mRNA-1273-gegen-Omikron-teilweise-ausgleichen
-
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung
(Hinzugefügt: 04.12.2021 um 09:15 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)01405-7
-
Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
(Hinzugefügt: 01.12.2021 um 18:10 Uhr)
https://www.sciencedirect.com/science/article/pii/S2667193X21001307
-
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
(Hinzugefügt: 28.11.2021 um 15:14 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2
-
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
(Hinzugefügt: 25.11.2021 um 18:46 Uhr)
https://www.science.org/doi/10.1126/science.abm3425
-
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
(Hinzugefügt: 20.11.2021 um 11:06 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-fda-authorization-booster-dose-covid-19/
-
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
(Hinzugefügt: 19.11.2021 um 16:01 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00574-X/fulltext
-
Frankreich: Behörde rät von Moderna-Impfstoff für unter 30-Jährige ab
(Hinzugefügt: 19.11.2021 um 15:58 Uhr)
https://www.aerzteblatt.de/nachrichten/128910/Frankreich-Behoerde-raet-von-Moderna-Impfstoff-fuer-unter-30-Jaehrige-ab
-
MYOKARDITIS: ANWENDUNGSBESCHRÄNKUNGEN FÜR mRNA-IMPFSTOFF VON MODERNA IN NORDISCHEN LÄNDERN
(Hinzugefügt: 04.11.2021 um 19:04 Uhr)
https://www.arznei-telegramm.de/html/2021_10/2110079_02.html
-
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
(Hinzugefügt: 04.11.2021 um 08:41 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2115597
-
EU-Behörde empfiehlt Boosterimpfung mit Moderna-Vakzin
(Hinzugefügt: 26.10.2021 um 18:43 Uhr)
https://www.aerzteblatt.de/nachrichten/128481/EU-Behoerde-empfiehlt-Boosterimpfung-mit-Moderna-Vakzin
-
EU-Behörde empfiehlt Boosterimpfung mit Moderna-Vakzin
(Hinzugefügt: 26.10.2021 um 18:43 Uhr)
https://www.aerzteblatt.de/nachrichten/128481/EU-Behoerde-empfiehlt-Boosterimpfung-mit-Moderna-Vakzin
-
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
(Hinzugefügt: 26.10.2021 um 09:07 Uhr)
https://www.biorxiv.org/content/10.1101/2021.10.23.465542v1
-
Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates
(Hinzugefügt: 25.10.2021 um 07:26 Uhr)
https://www.science.org/doi/10.1126/science.abl8912
-
Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
(Hinzugefügt: 21.10.2021 um 11:06 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2114089
-
mRNA-1273 BOOSTER DOSE
(Hinzugefügt: 18.10.2021 um 10:39 Uhr)
https://www.fda.gov/media/152953/download
-
Fact Check: Have Finland, Sweden, Norway and Iceland 'Banned' Moderna Vaccine?
(Hinzugefügt: 18.10.2021 um 09:51 Uhr)
https://www.newsweek.com/fact-check-has-sweden-denmark-norway-iceland-banned-moderna-vaccine-1638563
-
FDA-Gremium empfiehlt Auffrischungsimpfungen mit Moderna
(Hinzugefügt: 16.10.2021 um 11:57 Uhr)
https://www.aerzteblatt.de/nachrichten/128200/FDA-Gremium-empfiehlt-Auffrischungsimpfungen-mit-Moderna
-
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
(Hinzugefügt: 16.10.2021 um 11:54 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2115596
-
Moderna will mRNA-Impfstoffe in Afrika herstellen
(Hinzugefügt: 12.10.2021 um 11:09 Uhr)
https://www.aerzteblatt.de/nachrichten/127946/Moderna-will-mRNA-Impfstoffe-in-Afrika-herstellen
-
Schweden und Dänemark setzen Moderna-Impfung für junge Menschen vorerst aus
(Hinzugefügt: 07.10.2021 um 06:56 Uhr)
https://www.spiegel.de/wissenschaft/medizin/corona-schweden-setzt-moderna-impfung-fuer-junge-menschen-vorerst-aus-a-d5105c58-28f3-4018-956a-ceb6d5e4c524
-
Moderna COVID-19 vaccine generates long-lasting immune memory
(Hinzugefügt: 06.10.2021 um 06:29 Uhr)
https://www.nih.gov/news-events/nih-research-matters/moderna-covid-19-vaccine-generates-long-lasting-immune-memory
-
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
(Hinzugefügt: 04.10.2021 um 09:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1
-
Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
(Hinzugefügt: 03.10.2021 um 07:57 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.29.21264089v1
-
Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial
(Hinzugefügt: 02.10.2021 um 18:34 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.28.21264252v1
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
(Hinzugefügt: 24.09.2021 um 11:09 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2113017
-
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
(Hinzugefügt: 23.09.2021 um 10:05 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1
-
SARS-CoV-2: Schutzwirkung von BNT162b2 lässt etwas schneller nach als bei mRNA-1273
(Hinzugefügt: 22.09.2021 um 10:31 Uhr)
https://www.aerzteblatt.de/nachrichten/127433/SARS-CoV-2-Schutzwirkung-von-BNT162b2-laesst-etwas-schneller-nach-als-bei-mRNA-1273
-
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
(Hinzugefügt: 20.09.2021 um 09:28 Uhr)
https://www.science.org/doi/10.1126/science.abj0299
-
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
(Hinzugefügt: 15.09.2021 um 16:08 Uhr)
https://www.science.org/doi/10.1126/science.abj9853
-
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
(Hinzugefügt: 15.09.2021 um 15:56 Uhr)
https://www.bmj.com/content/374/bmj.n1943
-
Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
(Hinzugefügt: 15.09.2021 um 15:37 Uhr)
https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
-
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
(Hinzugefügt: 15.09.2021 um 15:03 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2783797
-
Moderna-Ampullen in Japan mit Edelstahlpartikeln verunreinigt
(Hinzugefügt: 15.09.2021 um 14:57 Uhr)
https://www.aerzteblatt.de/nachrichten/126912/Moderna-Ampullen-in-Japan-mit-Edelstahlpartikeln-verunreinigt
-
COVID-19: Moderna beantragt allgemeine Zulassung für die dritte Dosis
(Hinzugefügt: 15.09.2021 um 14:37 Uhr)
https://www.aerzteblatt.de/nachrichten/127018/COVID-19-Moderna-beantragt-allgemeine-Zulassung-fuer-die-dritte-Dosis
-
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
(Hinzugefügt: 14.09.2021 um 07:27 Uhr)
https://www.science.org/doi/10.1126/science.abj4176
-
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
(Hinzugefügt: 26.08.2021 um 04:00 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-submission-biologics-license-application-us/
-
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
(Hinzugefügt: 24.08.2021 um 17:08 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4
-
Deutschland verzichtet auf Millionen Impfdosen von Moderna
(Hinzugefügt: 24.08.2021 um 16:59 Uhr)
https://www.br.de/nachrichten/deutschland-welt/deutschland-verzichtet-auf-millionen-corona-impfdosen-von-moderna,SfnLz7o?fbclid=IwAR2RpFiJqxWLrQOJMzia0AfFOgJtg6IVqFHcZJ51Ra5ZLNmvIoZGdz9VqNk
-
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
(Hinzugefügt: 24.08.2021 um 16:51 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2109522
-
Moderna gives bigger antibody boost than Pfizer in elderly: U of T researchers
(Hinzugefügt: 24.08.2021 um 16:34 Uhr)
https://www.utoronto.ca/news/moderna-gives-bigger-antibody-boost-pfizer-elderly-u-t-researchers
-
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
(Hinzugefügt: 14.08.2021 um 08:57 Uhr)
https://science.sciencemag.org/content/early/2021/08/11/science.abj4176.full
-
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
(Hinzugefügt: 06.08.2021 um 10:45 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial/
-
First results LUMC study skin vaccination with corona vaccine are promising
(Hinzugefügt: 04.08.2021 um 08:57 Uhr)
https://www.lumc.nl/over-het-lumc/nieuws/2021/juni/onderzoek-huidprik-veelbelovend/?year=2021&month=5
-
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
(Hinzugefügt: 03.08.2021 um 10:17 Uhr)
https://science.sciencemag.org/content/early/2021/07/29/science.abj0299.full
-
Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis
(Hinzugefügt: 13.07.2021 um 07:13 Uhr)
https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis
-
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
(Hinzugefügt: 13.07.2021 um 07:12 Uhr)
https://www.nature.com/articles/s41591-021-01446-y
-
Quarter-dose of Moderna COVID vaccine still rouses a big immune response
(Hinzugefügt: 09.07.2021 um 19:09 Uhr)
https://www.nature.com/articles/d41586-021-01893-0
-
Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory
(Hinzugefügt: 07.07.2021 um 07:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1
-
Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India
(Hinzugefügt: 05.07.2021 um 18:47 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-update-neutralizing-activity-its-covid/
-
Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine
(Hinzugefügt: 20.06.2021 um 17:44 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781173
-
Moderna beantragt EU-Zulassung für Impfung von Jugendlichen
(Hinzugefügt: 09.06.2021 um 19:42 Uhr)
https://www.t-online.de/gesundheit/krankheiten-symptome/id_90174104/corona-impfung-moderna-beantragt-eu-zulassung-fuer-jugendliche.html
-
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
(Hinzugefügt: 09.06.2021 um 19:18 Uhr)
https://stm.sciencemag.org/content/early/2021/06/08/scitranslmed.abi9915.1.full
-
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
(Hinzugefügt: 07.06.2021 um 08:01 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.05.21256716v1
-
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
(Hinzugefügt: 06.06.2021 um 14:58 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-initiation-rolling-submission-biologics
-
Vaccine shopping to avoid Moderna shot is 'alarming,' unnecessary and potentially harmful, doctors say
(Hinzugefügt: 25.05.2021 um 14:08 Uhr)
https://www.cbc.ca/news/canada/toronto/moderna-vaccine-preference-1.6034764
-
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
(Hinzugefügt: 25.05.2021 um 13:56 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.21.445189v1
-
Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
(Hinzugefügt: 22.05.2021 um 17:49 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075
-
Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination
(Hinzugefügt: 08.05.2021 um 12:13 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.06.21256403v1
-
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
(Hinzugefügt: 07.05.2021 um 06:34 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-first-quarter-fiscal-year-2021-financial-results
-
Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 Variants
(Hinzugefügt: 06.05.2021 um 09:25 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.04.21256537v1
-
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
(Hinzugefügt: 06.05.2021 um 09:09 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov/
-
Resilient Fc-Effector Functions Across SARS-CoV-2 Variants of Concern Following mRNA-1273 Vaccination
(Hinzugefügt: 29.04.2021 um 07:11 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3832979
-
Will Moderna COVID vaccine need a third dose? Here’s what we know so far
(Hinzugefügt: 24.04.2021 um 05:55 Uhr)
https://www.miamiherald.com/news/coronavirus/article250890694.html
-
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
(Hinzugefügt: 22.04.2021 um 12:30 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.20.440647v1
-
Moderna COVID vaccine could receive emergency authorization for children ages 12 to 15 within ‘weeks’
(Hinzugefügt: 20.04.2021 um 06:02 Uhr)
https://www.masslive.com/coronavirus/2021/04/moderna-covid-vaccine-could-receive-emergency-authorization-for-children-ages-12-to-15-within-weeks.html
-
https://www.nejm.org/doi/full/10.1056/NEJMc2103916
(Hinzugefügt: 17.04.2021 um 09:55 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103916
-
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
(Hinzugefügt: 15.04.2021 um 06:14 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1
-
Studie zu Corona-Vakzin Wirksamkeit von Moderna herabgestuft
(Hinzugefügt: 14.04.2021 um 08:08 Uhr)
https://amp.zdf.de/nachrichten/panorama/corona-impfstoff-moderna-wirksamkeit-100.html?utm_source=upday&utm_medium=referral
-
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
(Hinzugefügt: 14.04.2021 um 07:02 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-supply-updates-covid-19-vaccine/
-
Letter from the JCVI on use of the Moderna vaccine in the COVID-19 immunisation programme: 7 April 2021
(Hinzugefügt: 12.04.2021 um 18:07 Uhr)
https://www.gov.uk/government/publications/letter-from-the-health-and-social-care-secretary-on-use-of-the-moderna-vaccine/letter-from-the-jcvi-on-use-of-the-moderna-vaccine-in-the-covid-19-immunisation-programme-7-april-2021
-
People who got the Moderna COVID-19 vaccine say they have more side effects
(Hinzugefügt: 09.04.2021 um 06:14 Uhr)
https://www.theverge.com/2021/4/7/22371665/covid-vaccine-side-effects-moderna-pfizer
-
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
(Hinzugefügt: 08.04.2021 um 06:22 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103740
-
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
(Hinzugefügt: 07.04.2021 um 07:07 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103916
-
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine
(Hinzugefügt: 02.04.2021 um 20:03 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-storage-update-announces-us-fda-authorizes-15/
-
50 Prozent mehr pro Ampulle US-Behörde erweitert Moderna-Zulassung
(Hinzugefügt: 02.04.2021 um 20:00 Uhr)
https://www.n-tv.de/panorama/US-Behoerde-erweitert-Moderna-Zulassung-article22467976.html
-
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
(Hinzugefügt: 30.03.2021 um 08:25 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
-
Diesen Brief schrieb Lonza an Bundesrat Alain Berset
(Hinzugefügt: 29.03.2021 um 06:37 Uhr)
https://www.20min.ch/story/diesen-brief-schrieb-lonza-an-bundesrat-alain-berset-392552952538
-
Infection and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
(Hinzugefügt: 21.03.2021 um 07:11 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00137-2
-
CORRESPONDENCE Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
(Hinzugefügt: 18.03.2021 um 05:45 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102179
-
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
(Hinzugefügt: 17.03.2021 um 02:17 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-0/
-
Lonza gets licence to make ingredients for Moderna vaccine
(Hinzugefügt: 16.03.2021 um 08:02 Uhr)
https://www.reuters.com/article/us-health-coronavirus-lonza-moderna-idUSKBN2B72BB
-
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
(Hinzugefügt: 15.03.2021 um 15:05 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/first-participants-dosed-phase-1-study-evaluating-mrna-1283/
-
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
(Hinzugefügt: 11.03.2021 um 08:38 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-study-evaluating/
-
Bern: Merkblatt: Aufziehen und Verimpfen von Impfstoffen ohne Totvolumenverlust
(Hinzugefügt: 10.03.2021 um 08:13 Uhr)
https://www.gef.be.ch/gef/de/index/Corona/Corona/corona_impfung_bern/corona_impfung_informationen_fuer_fachpersonen.assetref/dam/documents/GEF/GS/de/impfen/Fachpersonen/Merkblatt_%20Aufziehen%20und%20Verimpfen%20von%20Impfstoffen%20ohne%20Totvolumenverlust
-
SARS-CoV-2: Allergische Spätreaktion auf mRNA-Vakzine von Moderna
(Hinzugefügt: 05.03.2021 um 06:52 Uhr)
https://www.aerzteblatt.de/nachrichten/121767/SARS-CoV-2-Allergische-Spaetreaktion-auf-mRNA-Vakzine-von-Moderna
-
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
(Hinzugefügt: 05.03.2021 um 06:44 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102131
-
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
(Hinzugefügt: 04.03.2021 um 08:06 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102131
-
Moderna to begin trial of new COVID vaccine to address virus variant first found in South Africa
(Hinzugefügt: 25.02.2021 um 19:59 Uhr)
https://eu.usatoday.com/story/news/health/2021/02/24/moderna-begin-trial-new-covid-vaccine-address-virus-variant/6802803002/
-
Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine
(Hinzugefügt: 25.02.2021 um 19:51 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-additional-capital-investments-increase-global/
-
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study
(Hinzugefügt: 25.02.2021 um 19:51 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine/
-
Moderna Provides U.S. COVID-19 Vaccine Supply Update
(Hinzugefügt: 17.02.2021 um 03:25 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-us-covid-19-vaccine-supply-update-0/
-
Moderna will mehr Impfstoff pro Ampulle abfüllen
(Hinzugefügt: 16.02.2021 um 11:39 Uhr)
https://www.aerzteblatt.de/nachrichten/121154/Moderna-will-mehr-Impfstoff-pro-Ampulle-abfuellen
-
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
(Hinzugefügt: 15.02.2021 um 08:48 Uhr)
https://www.sciencedirect.com/science/article/pii/S0264410X21001535
-
Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines
(Hinzugefügt: 04.02.2021 um 09:40 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2776229
-
Luck, foresight and science: How an unheralded team developed a COVID-19 vaccine in record time
(Hinzugefügt: 31.01.2021 um 10:08 Uhr)
https://eu.usatoday.com/in-depth/news/investigations/2021/01/26/moderna-covid-vaccine-science-fast/6555783002/
-
Moderna Provides U.S. COVID-19 Vaccine Supply Update
(Hinzugefügt: 27.01.2021 um 09:36 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-us-covid-19-vaccine-supply-update/
-
Vaccine 2.0: Moderna and other companies plan tweaks that would protect against new coronavirus mutations
(Hinzugefügt: 27.01.2021 um 09:30 Uhr)
https://www.sciencemag.org/news/2021/01/vaccine-20-moderna-and-other-companies-plan-tweaks-would-protect-against-new
-
Dr. Anthony Fauci Applauds Moderna's Program to Create COVID-19 Booster for South African Variant
(Hinzugefügt: 26.01.2021 um 12:53 Uhr)
https://www.newsweek.com/dr-anthony-fauci-applauds-modernas-program-create-covid-19-booster-south-african-variant-1564215
-
Moderna coronavirus vaccine doses can be spaced up to six weeks but pregnant women should avoid jab, says WHO
(Hinzugefügt: 26.01.2021 um 12:53 Uhr)
https://www.independent.co.uk/news/health/moderna-vaccine-covid-spacing-pregnant-b1792784.html
-
SARS-CoV-2: Schutzwirkung von Moderna-Impfstoff gegen südafrikanische Variante könnte schnell nachlassen
(Hinzugefügt: 26.01.2021 um 08:41 Uhr)
https://www.aerzteblatt.de/nachrichten/120497/SARS-CoV-2-Schutzwirkung-von-Moderna-Impfstoff-gegen-suedafrikanische-Variante-koennte-schnell-nachlassen
-
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
(Hinzugefügt: 26.01.2021 um 08:38 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1
-
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
(Hinzugefügt: 26.01.2021 um 08:38 Uhr)
https://investors.modernatx.com/node/10841/pdf
-
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
(Hinzugefügt: 26.01.2021 um 08:35 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against/
-
COVID-19-IMPFSTOFF VON MODERNA
(Hinzugefügt: 22.01.2021 um 19:15 Uhr)
https://www.arznei-telegramm.de/html/2021_01/2101001_02.html
-
SARS-CoV-2: Laborexperimente deuten auf verminderte Schutzwirkung gegen neue Varianten hin
(Hinzugefügt: 22.01.2021 um 09:10 Uhr)
https://www.aerzteblatt.de/nachrichten/120379/SARS-CoV-2-Laborexperimente-deuten-auf-verminderte-Schutzwirkung-gegen-neue-Varianten-hin
-
SCHWERE ALLERGISCHE IMPFREAKTIONEN Moderna: Über 300.000 Impfungen sollen zurückgehalten werden
(Hinzugefügt: 19.01.2021 um 12:41 Uhr)
https://m.apotheke-adhoc.de/nachrichten/detail/internationales/moderna-ueber-300000-impfungen-sollen-zurueckgehalten-werden-schwere-allergische-impfreaktionen/
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
(Hinzugefügt: 19.01.2021 um 07:14 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2032195
-
California State Epidemiologist Statement Recommending Providers Pause Administration of Single Lot of Moderna COVID-19 Vaccine
(Hinzugefügt: 18.01.2021 um 21:07 Uhr)
https://www.cdph.ca.gov/Programs/OPA/Pages/NR21-021.aspx
-
Moderna believes it could update its coronavirus vaccine without a big new trial
(Hinzugefügt: 15.01.2021 um 06:52 Uhr)
https://www.technologyreview.com/2021/01/13/1016098/moderna-variant-coronavirus-vaccine-update/
-
Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland
(Hinzugefügt: 13.01.2021 um 08:23 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/swissmedic-authorizes-covid-19-vaccine-moderna-use-switzerland/
-
Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
(Hinzugefügt: 11.01.2021 um 08:20 Uhr)
https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
-
Ausschuss für Humanarzneimittel CHMP empfiehlt bedingte Zulassung für den COVID-19-Impfstoff von Moderna
(Hinzugefügt: 10.01.2021 um 09:33 Uhr)
https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-ema-empfiehlt-bedingte-zulassung-covid-19-impfstoff-moderna.html;jsessionid=452AFDF4FA79320EA01A4E9CD0947A94.intranet221?nn=221090
-
Paul- Ehrlich- Institut: Europäische Kommission erteilt Zulassung für den COVID-19-Impfstoff von Moderna für die Europäische Union
(Hinzugefügt: 10.01.2021 um 09:32 Uhr)
https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-eu-zulassung-covid-19-impfstoff-moderna.html;jsessionid=452AFDF4FA79320EA01A4E9CD0947A94.intranet221?nn=221090
-
Japanese approval of Moderna COVID-19 vaccine unlikely before May
(Hinzugefügt: 09.01.2021 um 10:24 Uhr)
https://www.japantimes.co.jp/news/2021/01/07/national/science-health/japan-moderna-vaccine/
-
Moderna vaccine becomes third COVID-19 vaccine approved by UK regulator
(Hinzugefügt: 08.01.2021 um 18:29 Uhr)
https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator
-
Maintaining Safety with SARS-CoV-2 Vaccines
(Hinzugefügt: 08.01.2021 um 10:17 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMra2035343
-
Moderna CEO says vaccine likely to protect for 'couple of years'
(Hinzugefügt: 08.01.2021 um 09:41 Uhr)
https://www.reuters.com/article/us-health-coronavirus-moderna-vaccine/moderna-ceo-says-vaccine-likely-to-protect-for-couple-of-years-idUSKBN29C0YK
-
U.S. officials report more severe allergic reactions to COVID-19 vaccines
(Hinzugefügt: 07.01.2021 um 05:15 Uhr)
https://www.reuters.com/article/us-health-coronavirus-vaccines-allergy-idUSKBN29B2GS
-
Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data
(Hinzugefügt: 07.01.2021 um 04:55 Uhr)
https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/
-
EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU
(Hinzugefügt: 07.01.2021 um 04:53 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu
-
Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel
(Hinzugefügt: 05.01.2021 um 16:57 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use/
-
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
(Hinzugefügt: 05.01.2021 um 08:18 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines
-
Moderna Provides COVID-19 Vaccine Supply Update
(Hinzugefügt: 05.01.2021 um 08:01 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-covid-19-vaccine-supply-update/
-
Peer-reviewed report on Moderna COVID-19 vaccine publishes
(Hinzugefügt: 01.01.2021 um 19:17 Uhr)
https://www.nih.gov/news-events/news-releases/peer-reviewed-report-moderna-covid-19-vaccine-publishes
-
Kanada erlaubt Einsatz von Modernas Coronaimpfstoff
(Hinzugefügt: 28.12.2020 um 19:12 Uhr)
https://www.aerzteblatt.de/nachrichten/119732/Kanada-erlaubt-Einsatz-von-Modernas-Coronaimpfstoff
-
Celebrities beware! Moderna vaccine can cause swelling in people with facial fillers, dermatologist warns
(Hinzugefügt: 26.12.2020 um 10:04 Uhr)
https://www.dailymail.co.uk/news/article-9087415/Moderna-vaccine-causes-swelling-lip-fillers-warned.html
-
Boston Doctor Reports Serious Allergic Reaction After Getting Moderna’s Covid Vaccine
(Hinzugefügt: 26.12.2020 um 10:04 Uhr)
https://www.nytimes.com/2020/12/25/health/Covid-moderna-vaccine-allergies.html?action=click&module=Top%20Stories&pgtype=Homepage
-
Regulatory Decision Summary - Moderna COVID-19 Vaccine - Health Canada
(Hinzugefügt: 23.12.2020 um 20:28 Uhr)
https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736
-
Dr Fauci gives thumbs up as he receives Covid vaccine
(Hinzugefügt: 23.12.2020 um 08:41 Uhr)
https://www.independent.co.uk/news/world/americas/anthony-fauci-covid-vaccine-moderna-b1777697.html
-
Der Impfstoff mRNA-1273 (Moderna) zur Impfung gegen Corona
(Hinzugefügt: 23.12.2020 um 08:31 Uhr)
https://www.gesundheitsinformation.de/der-impfstoff-mrna-1273-moderna-zur-impfung-gegen.3544.de.html?part=corm-co
-
Canada: Statement on the U.S. authorization of the Moderna COVID-19 vaccine
(Hinzugefügt: 21.12.2020 um 10:53 Uhr)
https://www.canada.ca/en/health-canada/news/2020/12/statement-on-the-us-authorization-of-the-moderna-covid-19-vaccine.html
-
EU-Kommission zieht Option auf weitere 80 Millionen Impfstoffdosen von Moderna
(Hinzugefügt: 20.12.2020 um 09:30 Uhr)
https://www.aerzteblatt.de/nachrichten/119591/EU-Kommission-zieht-Option-auf-weitere-80-Millionen-Impfstoffdosen-von-Moderna
-
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
(Hinzugefügt: 19.12.2020 um 09:27 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid
-
Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine
(Hinzugefügt: 18.12.2020 um 10:32 Uhr)
https://www.ema.europa.eu/en/news/update-assessment-marketing-authorisation-application-modernas-mrna-1273-covid-19-vaccine
-
Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States
(Hinzugefügt: 18.12.2020 um 10:20 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-advisory-committee-vote-supporting/
-
Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Announcement
(Hinzugefügt: 17.12.2020 um 18:24 Uhr)
https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement
-
SARS-CoV-2: FDA bescheinigt Impfstoff von Moderna gute Wirkung und hohe Sicherheit
(Hinzugefügt: 16.12.2020 um 07:54 Uhr)
https://www.aerzteblatt.de/nachrichten/119425/SARS-CoV-2-FDA-bescheinigt-Impfstoff-von-Moderna-gute-Wirkung-und-hohe-Sicherheit
-
FDA Briefing Document Moderna COVID-19 Vaccine
(Hinzugefügt: 15.12.2020 um 18:59 Uhr)
https://www.fda.gov/media/144434/download
-
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults List of authors.
(Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
(Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2032195
-
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
(Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483
-
trial protocol
(Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_protocol.pdf
-
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents
(Hinzugefügt: 11.12.2020 um 08:07 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid/